IV gentamicin shows promise for genetic blistering skin disorder

Systemic readthrough therapy promotes wound closure in paediatric patients with junctional epidermolysis bullosa, US clinicians say

A single course of IV gentamicin may be a safe and readily available systemic therapy for patients with junctional epidermolysis bullosa, according to results from a small pilot trial.

While the long-term safety and efficacy remains unknown, US researchers say their findings provide a glimmer of hope for those born with the incurable blistering skin disorder.

In a previous study, the University of Southern California-led team had shown that topical gentamicin generated new laminin 332 — which is essential for epithelial cell adhesion to the